Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Marker

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Journal of Autoimmunity|November 7, 2002
NKT cell defects in NOD mice suggest therapeutic opportunitiesAnjli Kukreja, Guilia Costi, John Marker, et al.
The Journal of Clinical Investigation|January 10, 2002
Multiple immuno-regulatory defects in type-1 diabetesAnjli Kukreja, Giulia Cost, John Marker, et al.
Annals of the New York Academy of Sciences|February 1, 2005
Oral insulin therapy to prevent progression of immune-mediated (type 1) diabetesBerrin Ergun-Longmire, John Marker, Adina Zeidler, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Journal of Autoimmunity|November 7, 2002
NKT cell defects in NOD mice suggest therapeutic opportunitiesAnjli Kukreja, Guilia Costi, John Marker, et al.
The Journal of Clinical Investigation|January 10, 2002
Multiple immuno-regulatory defects in type-1 diabetesAnjli Kukreja, Giulia Cost, John Marker, et al.
Annals of the New York Academy of Sciences|February 1, 2005
Oral insulin therapy to prevent progression of immune-mediated (type 1) diabetesBerrin Ergun-Longmire, John Marker, Adina Zeidler, et al.
Pageof 1